Prothena posts Q4 2025 net loss $21.6M; full-year loss $244.1M; 2026 cash burn guide $50-55M

PROTHENA CORP PUBLIC LTD CO

2025-FY EPS reported -$4.53 revenue$9,684,000

Net loss $21.6M ($0.40 EPS) in Q4 vs $58.0M loss ($1.08 EPS) in Q4 2024; full-year loss $244.1M ($4.53 EPS).
Total revenue $21K in Q4 vs $2.1M a year ago; full-year revenue $9.7M vs $135.2M in 2024.
Cash & restricted cash $308.4M at Dec 31, 2025; no debt; shares outstanding ~53.8M.
2026 guidance: net cash used in ops $50-55M; year-end cash ~$255M; excludes up to $105M milestones.
Partners Roche, Novo Nordisk, BMS initiated Phase 3 trials for prasinezumab, coramitug, and BMS-986446.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.